Statera Biopharma (STAB) 10-Q 10 Nov 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Nov. 06, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Trading Symbol	'CBLI	'
Entity Registrant Name	'CLEVELAND BIOLABS INC	'
Entity Central Index Key	'0001318641	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	57,148,241

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 30, 2014	Dec. 31, 2013
Current assets:	'	'
Cash and cash equivalents	$7,877,432	$10,048,466
Short-term investments	1,269,467	305,538
Accounts receivable	175,191	458,391
Other current assets	365,461	344,386
Total current assets	9,687,551	11,156,781
Equipment, net	287,827	457,912
Restricted cash	2,427,874	2,921,724
Other long-term assets	65,192	159,224
Total assets	12,468,444	14,695,641
Current liabilities:	'	'
Accounts payable	889,402	794,397
Accrued expenses	1,796,382	2,445,446
Deferred revenue	356,580	1,069,438
Accrued warrant liability	1,861,013	1,241,311
Current portion of notes payable	735,654	351,527
Current portion of capital lease obligation	29,560	83,634
Total current liabilities	5,668,591	5,985,753
Noncurrent portion of capital lease obligation	'	7,522
Long-term debt	3,479,396	7,121,388
Commitments and contingencies	'	'
Total liabilities	9,147,987	13,114,663
Stockholders' equity:	'	'
Preferred stock, $.005 par value; 10,000,000 shares authorized, 0 shares issued and outstanding as of September 30, 2014 and December 31, 2013, respectively	'	'
Common stock, $.005 par value; 160,000,000 shares authorized, 57,110,198 and 45,182,114 shares issued and outstanding as of September 30, 2014 and December 31, 2013, respectively	285,551	225,911
Additional paid-in capital	134,773,438	125,508,471
Other comprehensive income/(loss)	-201,214	307,339
Accumulated deficit	-145,207,333	-135,564,666
Total Cleveland BioLabs, Inc. stockholders' deficit	-10,349,558	-9,522,945
Noncontrolling interest in stockholders' equity	13,670,015	11,103,923
Total stockholders' equity	3,320,457	1,580,978
Total liabilities and stockholders' equity	$12,468,444	$14,695,641

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]	'	'
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	160,000,000	160,000,000
Common stock, shares issued	57,110,198	45,182,114
Common stock, shares outstanding	57,110,198	45,182,114

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenues:	'	'	'	'
Grants and contracts	$415,126	$1,635,600	$2,311,467	$4,616,334
Operating expenses:	'	'	'	'
Research and development	2,068,245	4,205,238	6,832,241	14,909,882
General and administrative	1,785,620	3,286,830	6,449,531	9,787,053
Total operating expenses	3,853,865	7,492,068	13,281,772	24,696,935
Loss from operations	-3,438,739	-5,856,468	-10,970,305	-20,080,601
Other income (expense):	'	'	'	'
Interest and other income (expense)	-68,932	97,534	-1,010,640	225,299
Foreign exchange gain (loss)	-271,699	-15,057	-330,876	59,853
Change in value of warrant liability	-836,293	1,163,030	1,663,390	510,919
Total other income (expense)	-1,176,924	1,245,507	321,874	796,071
Net loss	-4,615,663	-4,610,961	-10,648,431	-19,284,530
Net loss	-4,615,663	-4,610,961	-10,648,431	-19,284,530
Net loss attributable to noncontrolling interests	519,529	519,765	1,005,764	2,386,900
Net loss attributable to Cleveland BioLabs, Inc.	($4,096,134)	($4,091,196)	($9,642,667)	($16,897,630)
Net loss available to common stockholders per share of common stock, basic and diluted	($0.07)	($0.09)	($0.18)	($0.38)
Weighted average number of shares used in calculating net income (loss) per share, basic and diluted	57,110,198	45,061,274	53,016,147	44,946,340

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (Loss) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Statement of Comprehensive Income [Abstract]	'	'	'	'
Net loss including noncontrolling interests	($4,615,663)	($4,610,961)	($10,648,431)	($19,284,530)
Other comprehensive loss	'	'	'	'
Foreign currency translation adjustment	-819,694	35,821	-912,108	-404,248
Comprehensive loss including noncontrolling interests	-5,435,357	-4,575,140	-11,560,539	-19,688,778
Comprehensive loss attributable to noncontrolling interests	901,512	502,891	1,409,319	2,552,089
Comprehensive loss attributable to Cleveland BioLabs, Inc.	($4,533,845)	($4,072,249)	($10,151,220)	($17,136,689)

Consolidated_Statement_of_Stoc

Consolidated Statement of Stockholders' Equity (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]	Noncontrolling Interests [Member]
Beginning balance at Dec. 31, 2013	$1,580,978	$225,911	$125,508,471	$307,339	($135,564,666)	$11,103,923
Beginning balance, Shares at Dec. 31, 2013	'	45,182,114	'	'	'	'
Stock based compensation	546,475	'	546,475	'	'	'
Stock based compensation, Shares	'	'	'	'	'	'
Issuance of shares for compensation	15,625	115	15,510	'	'	'
Issuance of shares for compensation, Shares	'	22,978	'	'	'	'
Issuance of common stock, net of offering costs	9,802,118	59,525	9,742,593	'	'	'
Issuance of common stock, net of offering costs, shares	'	11,905,106	'	'	'	'
Allocation of equity proceeds to fair value of warrants	-2,216,593	'	-2,216,593	'	'	'
Noncontrolling interest capital contribution	5,152,393	'	1,176,982	'	'	3,975,411
Net loss	-10,648,431	'	'	'	-9,642,667	-1,005,764
Foreign currency translation	-912,108	'	'	-508,553	'	-403,555
Ending balance at Sep. 30, 2014	$3,320,457	$285,551	$134,773,438	($201,214)	($145,207,333)	$13,670,015
Ending balance, Shares at Sep. 30, 2014	'	57,110,198	'	'	'	'

Consolidated_Statement_of_Stoc1

Consolidated Statement of Stockholders' Equity (Parenthetical) (Common Stock [Member], USD $)	9 Months Ended
	Sep. 30, 2014
Common Stock [Member]	'
Offering costs	$697,882

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities:	'	'
Net loss	($10,648,431)	($19,284,530)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation	154,602	284,278
Amortization	609,837	'
Loss on equipment disposal	24,685	'
Noncash compensation	252,651	1,591,986
Warrant issuance costs	171,116	'
Change in value of warrant liability	-1,663,390	-510,919
Changes in operating assets and liabilities:	'	'
Accounts receivable	361,391	-565,336
Other current assets	-74,659	452,798
Other long-term assets	19,592	-3,995
Accounts payable	132,499	-310,150
Deferred revenue	-588,759	-1,102,472
Accrued expenses	-67,699	525,198
Net cash used in operating activities	-11,316,565	-18,923,142
Cash flows from investing activities:	'	'
Purchase of short-term investments	-1,412,916	'
Sale of short-term investments	282,583	2,213,999
Purchase of equipment	-12,328	-125,218
Increase in restricted cash	'	-1,421,861
Net cash provided by (used in) investing activities	-1,142,661	666,920
Cash flows from financing activities:	'	'
Issuance of common stock, net of offering costs	9,697,501	'
Net proceeds/(repayment) of long-term debt	-4,000,000	7,297,675
Noncontrolling interest capital contribution to Incuron, LLC	5,152,393	'
Exercise of options	'	12,392
Repayment of capital lease obligation	-61,596	-59,012
Net cash provided by financing activities	10,788,298	7,251,055
Effect of exchange rate change on cash and equivalents	-500,106	-333,995
Decrease in cash and cash equivalents	-2,171,034	-11,339,162
Cash and cash equivalents at beginning of period	10,048,466	25,652,083
Cash and cash equivalents at end of period	7,877,432	14,312,921
Supplemental disclosure of cash flow information:	'	'
Cash paid during the period for interest	415,621	17,105
Supplemental schedule of noncash financing activities:	'	'
Noncash financing costs on common stock offering	50,505	'
Noncash warrant issuance costs	$15,993	$117,999

Description_of_Business

Description of Business	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Description of Business	'
	1.  Description of Business
	Cleveland BioLabs, Inc., or CBLI, or the Company, is an innovative biopharmaceutical company seeking to develop first-in-class pharmaceuticals designed to address diseases with significant unmet medical need. Our lead product candidates are entolimod, which we are developing for a biodefense indication and as an oncology drug, and Curaxin CBL0137, our lead oncology product candidate. We conduct business in the United States and in the Russian Federation, or Russia, through several legal entities, some of which are majority-owned in collaboration with financial partners.
	CBLI was incorporated in Delaware in June 2003 and is headquartered in Buffalo, New York. As of September 30, 2014, CBLI had one wholly-owned subsidiary, Biolab 612, LLC, or Biolab 612, which began operations in 2012, and two majority-owned operating subsidiaries, Incuron, LLC, or Incuron, and Panacela Labs, Inc., or Panacela, which were formed in 2010 and 2011, respectively. Additionally, Panacela has a wholly-owned operating subsidiary, Panacela Labs, LLC.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	2.  Summary of Significant Accounting Policies
	Basis of Presentation and Consolidation
	The accompanying consolidated financial statements include the accounts of CBLI and its subsidiaries, BioLab 612, Incuron and Panacela. All significant intercompany balances and transactions have been eliminated in consolidation.
	The unaudited consolidated financial statements included herein have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP, for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission, or the SEC. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013, as filed with the SEC.
	In the opinion of the Company’s management, any adjustments contained in the accompanying unaudited consolidated financial statements are of a normal recurring nature, and are necessary to present fairly the financial position of the Company as of September 30, 2014, along with its results of operations for the three and nine month periods ended September 30, 2014 and 2013 and cash flows for the nine month periods ended September 30, 2014 and 2013. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year.
	As of September 30, 2014, the Company had $4.9 million of cash and cash equivalents available for the general use which management believes will be sufficient to support operations into the first quarter of 2015. To ensure continuing operations beyond the first quarter of 2015, management is evaluating all opportunities to secure additional financing, including investments from non-controlling interests, the issuance of equity and additional revenues from the US or Russian governments. Management believes that sufficient sources of financing will be available to support operations into the future, however there can be no assurances at this time. These matters raise substantial doubt about the Company’s ability to continue as a going concern. These financial statements have been prepared under the assumption that the Company will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty.
	Recent Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2014-09, Revenue from Contracts with Customers, which updates the principles for recognizing revenue. ASU 2014-09 also amends the required disclosures of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. The Company is evaluating the potential impacts of the new standard on its existing revenue recognition policies and procedures.
	In June 2014, the FASB issued ASU 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. ASU 2014-12 requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition, and as such, the performance target should not be reflected in estimating the grant-date fair value of the award. ASU 2014-12 is effective for annual reporting periods beginning after December 15, 2015, with early adoption permitted. The Company is evaluating the potential impacts of the new standard on its existing stock-based compensation plans.
	In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, ASU 2014-15 requires that an entity’s management evaluate whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. ASU 2014-15 is effective for annual periods beginning after December 15, 2016 and for interim periods thereafter. The Company is evaluating the potential impacts of this new standard on its quarterly reporting process.
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
	Cash and Cash Equivalents
	Of the $7.9 million and $10.0 million of cash and cash equivalents at September 30, 2014 and December 31, 2013, respectively, only $3.5 million at December 31, 2013 consisted of highly liquid investments with maturities of 90 days or less when purchased. These investments consist of commercial paper, short-term debt securities, time deposits and investments in money market funds with commercial banks and financial institutions. As of September 30, 2014, $3.0 million of the Company’s cash and cash equivalents was restricted to the use of its majority-owned subsidiaries, leaving $4.9 million available for general use.
	Significant Customers and Accounts Receivable
	Grant and contract revenue from the U.S. government accounted for 0% and 1.0% of total revenue for the three and nine months ended September 30, 2014, respectively, and 48.1% and 39.5% of total revenue for the three and nine months ended September 30, 2013, respectively. Grant and contract revenue received by the Company’s subsidiaries from Russian government agencies accounted for 100% and 99.0% of total revenues for the three and nine months ended September 30, 2014, respectively, and 51.9% and 60.5% of total revenues for the three and nine months ended September 30, 2013, respectively. Although the Company anticipates ongoing U.S. and Russian government contract and grant revenue, there is no guarantee that these revenue streams will continue in the future.
	Accounts receivable consist of amounts due under reimbursement contracts with certain government and foreign entities. The Company extends unsecured credit to customers under normal trade agreements, which generally require payment within 30 days.
	Management estimates an allowance for doubtful accounts that is based upon management’s review of delinquent accounts and an assessment of the Company’s historical evidence of collections. There were no allowances for doubtful accounts as of September 30, 2014 and December 31, 2013, as the collection history from the Company’s customers indicated that collection was probable.
	Intellectual Property
	Costs related to filing and pursuing patent applications are recognized as general and administrative expenses, or G&A expenses, as incurred, since the recoverability of such expenditures is uncertain. Upon marketing approval by the U.S. Food and Drug Administration, or FDA, or a respective foreign governing body, such costs will be capitalized and depreciated over the expected life of the related patent.
	Accounting for Stock-Based Compensation
	The 2006 Equity Incentive Plan, as amended, or the Plan, authorizes CBLI to grant (i) options to purchase common stock, (ii) restricted or unrestricted stock units, and (iii) stock appreciation rights, so long as the exercise or grant price of each are at least equal to the fair market value of the stock on the date of grant. As of September 30, 2014, an aggregate of 10.0 million shares of common stock were authorized for issuance under the Plan, of which a total of approximately 1.9 million shares of common stock remained available for future awards. A single participant cannot be awarded more than 400,000 shares annually. Awards granted under the Plan have a contractual life of no more than 10 years. The terms and conditions of equity awards (such as price, vesting schedule, term and number of shares) under the Plan are specified in an award document, and approved by the Company’s board of directors, compensation committee or its management delegees.
	In June 2013, the Company’s stockholders approved the 2013 Employee Stock Purchase Plan, or ESPP, which provides a means by which eligible employees of the Company and certain designated related corporations may be given an opportunity to purchase shares of Common Stock. As of September 30, 2014, there are 2.3 million shares of Common Stock reserved for purchase under the ESPP. The number of shares reserved for purchase under the ESPP increases on January 1 of each calendar year by the lesser of: (i) 10% of the total number of shares of Common Stock outstanding on December 31st of the preceding year, or (ii) 200,000 shares of Common Stock. The ESPP allows employees to use up to 15% of their compensation to purchase shares of Common Stock at an amount equal to 85% of the fair market value of the Company’s Common Stock on the offering date or the purchase date, whichever is less.
	The Company utilizes the Black-Scholes valuation model for estimating the fair value of all stock options granted where the vesting period is based on length of service or performance, while a Monte Carlo simulation model is used for estimating the fair value of stock options with market-based vesting conditions. Set forth below are the assumptions used in valuing the stock options granted and a discussion of the Company’s methodology for developing each of the assumptions used:
		For the nine months ended September 30,
		2014		2013
	Risk-free interest rate	1.59 - 1.98%		0.02 - 1.92%
	Expected dividend yield	0%		0%
	Expected life	5 - 6 Years		5 - 7.3 Years
	Expected volatility	71.24 - 77.99%		80.71 - 89.66%
	“Risk-free interest rate” means the range of U.S. Treasury rates with a term that most closely resembles the expected life of the option as of the date the option is granted.
	“Expected dividend yield” means the Company does not pay regular dividends on its common stock and does not anticipate paying any dividends in the foreseeable future.
	“Expected life” means the period of time that options granted are expected to remain outstanding, based wholly on the use of the simplified (safe harbor) method. The simplified method is used because the Company does not yet have adequate historical exercise information to estimate the expected life the options granted.
	“Expected volatility” means a measure of the amount by which a financial variable, such as share price, has fluctuated (historical volatility) or is expected to fluctuate (implied volatility) during a period. Expected volatility is based on the Company’s historical volatility and incorporates the volatility of the common stock of comparable companies when the expected life of the option exceeds the Company’s trading history.
	Income Taxes
	No income tax expense was recorded for the three and nine months ended September 30, 2014 and 2013, as the Company does not expect to have taxable income for 2014 and did not have taxable income in 2013. A full valuation allowance has been recorded against the Company’s deferred tax asset.
	Earnings (Loss) per Share
	Basic net income (loss) per share of common stock excludes dilution for potential common stock issuances and is computed by dividing net income (loss) by the weighted average number of shares outstanding for the period. Diluted net income (loss) per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. Diluted net loss per share is identical to basic net loss per share as potentially dilutive securities have been excluded from the calculation of diluted net loss per common share because the inclusion of such securities would be antidilutive.
	The Company has excluded the following outstanding warrants and options from the calculation of diluted net loss per share because all such securities were antidilutive for the periods presented:
		As of September 30,
	Common Equivalent Securities	2014			2013
	Warrants		18,565,024			10,534,245
	Options		5,799,914			5,608,912
	Total		24,364,938			16,143,157
	Contingencies
	From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business. The Company accrues for liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. For all periods presented, the Company is not a party to any pending material litigation that is estimable and probable of loss.

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value of Financial Instruments	'
	3.  Fair Value of Financial Instruments
	The Company measures and records warrant liabilities at fair value in the accompanying financial statements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value, includes:
	Level 1 – Observable inputs for identical assets or liabilities such as quoted prices in active markets;
	Level 2 – Inputs other than quoted prices in active markets that are either directly or indirectly observable; and
	Level 3 – Unobservable inputs in which little or no market data exists, which are therefore developed by the Company using estimates and assumptions that reflect those that a market participant would use.
	The following tables represent the Company’s fair value hierarchy for its financial liabilities measured at fair value on a recurring basis as of September 30, 2014 and December 31, 2013:
			As of September 30, 2014
			Level 1			Level 2			Level 3			Total
	Liabilities:
	Accrued warrant liability		$	—		$	—		$	1,861,013		$	1,861,013
	Total liabilities		$	—		$	—		$	1,861,013		$	1,861,013
			As of December 31, 2013
			Level 1			Level 2			Level 3			Total
	Liabilities:
	Accrued warrant liability		$	—		$	—		$	1,241,311		$	1,241,311
	Compensatory stock options not yet issued			—			—			309,450			309,450
	Total liabilities		$	—		$	—		$	1,550,761		$	1,550,761
	The Company uses the Black-Scholes model to measure the accrued warrant liability and its accrual for compensatory stock options not yet issued. The following are the assumptions used to measure the accrued warrant liability at September 30, 2014 and December 31, 2013, which were determined in a manner consistent with that described for grants of options to purchase common stock as set forth in Note 2:
			September 30, 2014			December 31, 2013
	Stock Price		$	0.46		$	1.17
	Exercise Price		$	0.505 - 5.00		$	1.60 - 5.00
	Term in years			0.40 - 6.29			0.59 - 1.91
	Volatility			66.57 - 86.88	%		42.52 - 76.03	%
	Annual rate of quarterly dividends			0	%		0	%
	Discount rate- bond equivalent yield			0.05 - 1.78	%		0.08 - 0.36	%
	The following table sets forth a summary of changes in the fair value of the Company’s Level 3 fair value measurements for the nine months ended September 30, 2014 and 2013:
			Three months ended September 30, 2014						Nine months ended September 30, 2014
			Accrued Warrant			Compensatory			Accrued Warrant			Compensatory
			Liability			Stock Options			Liability			Stock Options
						Not Yet Issued						Not Yet Issued
	Beginning balance		$	1,024,720		$	—		$	1,241,311		$	309,450
	Issuances			—			—			2,283,092			—
	Total (gains) or losses, realized and unrealized, included in earnings (1)(2)			836,293			—			(1,663,390	)		(21,055	)
	Settlements			—			—			—			(288,395	)
	Balance, September 30, 2014		$	1,861,013		$	—		$	1,861,013		$	—
			Three months ended September 30, 2013						Nine months ended September 30, 2013
			Accrued Warrant			Compensatory			Accrued Warrant			Compensatory
			Liability			Stock Options			Liability			Stock Options
						Not Yet Issued						Not Yet Issued
	Beginning balance		$	4,757,770		$	63,838		$	4,105,659		$	—
	Total (gains) or losses, realized and unrealized, included in earnings (1)			(1,163,029	)		—			(510,918	)		—
	Estimates and other changes in fair value (2)			—			102,945			—			166,783
	Balance, September 30, 2013		$	3,594,741		$	166,783		$	3,594,741		$	166,783
	-1	Unrealized gains or losses related to the accrued warrant liability were included as change in value of accrued warrant liability. Realized gains were $95,667 and $0 during the three months ended September 30, 2014 and 2013, respectively.
	-2	Expenses recorded for compensatory stock options not yet issued are included in research and development expense and general and administrative expense.
	As of September 30, 2014 and December 31, 2013, the Company had no assets or liabilities that were measured at fair value on a nonrecurring basis.
	The Company considers the accrued warrant liability and compensatory stock options not yet issued to be Level 3 because some of the inputs into the measurements are neither directly or indirectly observable. Both the accrued warrant liability and compensatory stock options not yet issued use management’s estimate for the expected term. Additionally, the number of compensatory options awarded involves an estimate of management’s performance in relation to the targets set forth in the Company’s Executive Compensation Plan. The following table summarizes the unobservable inputs into the fair value measurement for the accrued warrant liability as of September 30, 2014:
			September 30, 2014
	Description		Fair Value			Valuation Technique		Unobservable Input	Range
	Accrued warrant liability		$	1,861,013		Black-scholes pricing model		Expected term - Years	0.40 - 6.29
	Management believes the value of both the accrued warrant liability and compensatory stock options is more sensitive to a change in the Company’s stock price at the end of the respective reporting period as opposed to a change in one of the unobservable inputs described above.
	The carrying amounts of the Company’s short-term financial instruments, which include cash and cash equivalents, accounts receivable and accounts payable, approximate their fair values due to their short maturities.

Debt

Debt	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Debt	'
	4.  Debt
	On September 30, 2013, the Company entered into a Loan and Security Agreement with Hercules Technology II, L.P. and borrowed $6.0 million, the “Hercules Loan”. In addition to interest and principle payments, the Hercules Loan requires payment of $550,000 at maturity, or upon full repayment if sooner, “End-of-Term Fee”. In June 2014, CBLI repaid $4.0 million of the Hercules Loan using net proceeds of $3.3 million from a sale of equity more fully discussed in Note 5, along with $0.7 million of the Company’s cash. A 3% prepayment penalty was waived. On September 3, 2013, Panacela and Open Joint Stock Company “Rusnano”, or Rusnano, entered into a Convertible Loan Agreement pursuant to which Panacela borrowed $1.53 million from Rusnano, the “Rusnano Loan”. No amounts have been paid under the Rusnano Loan. The following schedule shows the remaining principal payments due under the Hercules Loan ($2.0 million as of September 30, 2014) for each of the twelve month periods commencing October 1, along with the End-of-Term Fee, and the Rusnano Loan, assuming the loan and compounded interest are paid at maturity in September 2015.
		September 30,
		Hercules		Rusnano		Total
		Loan		Loan
	2015	$	671,184	$	2,125,093	$	2,796,277
	2016		745,662		—		745,662
	2017		1,133,154		—		1,133,154
	2018		—		—		—
	2019		—		—		—
	Thereafter		—		—		—
		$	2,550,000	$	2,125,093	$	4,675,093

Stockholders_Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
Stockholders' Equity	'
	5.  Stockholders’ Equity
	On June 20, 2014, the Company completed a sale of units that were immediately separable into an aggregate of 6,167,400 shares of the Company’s common stock and warrants to purchase up to 3,083,700 additional shares of the Company’s common stock issuable upon the exercise of a warrant. Each unit was sold for $0.5675, which qualified as an “at market” transaction as determined by NASDAQ, resulting in net proceeds of approximately $3.3 million after deducting for placement agent fees and offering expenses. In connection with the sale, the Company issued Series J warrants for 3,083,700 shares of common stock to the purchasers, and 26,432 Series J warrants to the placement agent. Each Series J warrant has an exercise price of $0.56 per share, and will expire five years from the date of issuance. The sale also triggered a reduction in the exercise price of 4,577,444 of the Company’s warrants to $0.505.
	On January 16, 2014, the Company completed a public offering of 5,737,706 shares of the Company’s common stock at a price of $1.22 per share, resulting in net proceeds of approximately $6.4 million after deducting for placement agent fees and offering expenses. In connection with the offering, the Company issued Series A warrants for 2,868,853 shares of common stock and Series B warrants for 2,868,853 shares of common stock to the purchasers. Each Series A warrant has an exercise price of $1.22 per share, and will become exercisable nine months following the date of issuance and expire five years from the date of issuance. Each Series B warrant has an exercise price of $1.22 per share, and will become exercisable nine months following the date of issuance and expire 18 months from the date of issuance. In addition to the warrants issued to the purchasers, the Company also issued Series A warrants for an aggregate of 86,066 shares of common stock and Series B warrants for an aggregate of 86,066 shares of common stock to the placement agent as compensation for completing the offering. The warrants to the placement agent have the same terms, including exercise price, as the warrants issued to investors. The offering also triggered a reduction in the exercise price of 4,421,195 of the Company’s warrants to $1.22.
	The Series A and B warrants contain provisions that could require the Company to settle the warrants in cash, and accordingly, have been classified as a liability. The fair value of the Series A and B warrants amounted to $2,283,092 and was determined based on the following assumptions using the Black-Scholes valuation model:
		September 30, 2014
	Stock Price	$	1.23
	Exercise Price	$	1.22
	Term in years		0.75 - 2.50
	Volatility		43.06 - 79.86	%
	Annual rate of quarterly dividends		0	%
	Discount rate- bond equivalent yield		0.09 - 0.58	%
	On September 4, 2014, the Company and certain investors in the January 16, 2014 public offering discussed above amended the Securities Purchase Agreement to remove restrictions on the Company’s ability to issue securities involving a variable rate transaction, as therein defined. In addition, the same investors returned Series B Warrants to purchase, in the aggregate, 2,049,180 shares of the Company’s common stock for cancellation. In exchange for these concessions, the Company agreed to extend the expiration dates from January 16, 2019 to January 16, 2021 for Series A Warrants to purchase 2,049,180 shares of the Company’s common stock, and reduced the exercise price from $1.22 to $1.02.
	On September 29, 2014, the Company and certain investors amended a Securities Purchase Agreement, dated as of February 13, 2009, to remove restrictions on the Company’s ability to issue securities involving a variable rate transaction, as therein defined. In exchange, the Company agreed to extend the expiration dates from February 13, 2016 to March 30, 2018 on Series D warrants to purchase 3,485,810 shares of the Company’s common stock, and revised the anti-dilution provision in the Series D warrants to include variable rate transactions.
	The Company has granted options to purchase shares of common stock. The following is a summary of option award activity during the nine months ended September 30, 2014:
		Nine Months Ended September 30, 2014
		Total Stock			Weighted Average		Nonvested Stock			Weighted Average
		Options			Exercise Price per		Options			Grant Date Fair
		Outstanding			Share					Value per Share
	December 31, 2013		5,564,833		$	4.14		594,479		$	1.5
	Granted		991,000			0.62		48,125			0.34
	Vested		—			—		(96,875	)		2.68
	Exercised		—			—		—			—
	Forfeited, Canceled		(755,919	)		4.3		(113,750	)		1.45
	September 30, 2014		5,799,914		$	3.52		431,979		$	1.11
	The following is a summary of outstanding stock options as of September 30, 2014:
		As of September 30, 2014
		Stock Options			Vested Stock
		Outstanding			Options
	Quantity		5,799,914			5,367,935
	Weighted-average exercise price	$	3.52		$	3.69
	Weighted Average Remaining Contractual Term (in Years)		6.6			6.43
	Intrinsic value	$	—		$	—
	For the nine months ended September 30, 2014 and 2013, the Company granted 991,000 and 898,604 stock options, respectively, with a weighted-average grant date fair value of $0.38 and $1.21 respectively. For the nine months ended September 30, 2014 and 2013, the total fair value of options vested was $261,283 and $858,037, respectively.
	As of September 30, 2014, total compensation cost not yet recognized related to unvested stock options was $128,913. The Company expects to recognize this cost over a weighted average period of approximately 0.49 years.

Warrants

Warrants	9 Months Ended
	Sep. 30, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Warrants	'
	6. Warrants
	In connection with sales of the Company’s common stock and the issuance of debt instruments, warrants were issued which presently have exercise prices ranging from $0.505 to $5.00. The warrants expire between one and seven years from the date of grant, and are subject to the terms applicable in each agreement. As of September 30, 2014, the Company had warrants outstanding that are exercisable up to 17,505,032 shares of common stock, with a weighted average exercise price of $1.69 per share. In addition, the Company has issued a warrant to Rusnano, our financial partner in Panacela, that can only be exercised in the event Panacela defaults on a loan from Rusnano, the “Rusnano Warrant” and the “Rusnano Loan.” The maximum number of shares issuable under the Rusnano Warrant at the warrant’s termination date of December 31, 2016 is 1,059,992. If Panacela was in default under the loan at September 30, 2014, the shares issuable under the Rusnano Warrant would be 739,920. At September 30, 2014 Panacela was not in default of the Rusnano Loan.

Noncontrolling_Interests

Noncontrolling Interests	9 Months Ended
	Sep. 30, 2014
Noncontrolling Interest [Abstract]	'
Noncontrolling Interests	'
	7.  Noncontrolling Interests
	On June 20, 2014, Bioprocess Capital Ventures, or BCV, our financial partner in Incuron, contributed 100.0 million Russian rubles (approximately $2.9 million) to Incuron, which increased its ownership interest from 40.78% to 46.06% and decreased CBLI’s ownership percentage from 59.22% to 53.94%. The effect of this change in CBLI’s ownership interest in Incuron on CBLI’s equity is shown on the consolidated statement of stockholders’ equity. On August 5, 2014, BCV contributed an additional approximately 80 million Russian rubles (approximately $2.3 million) to Incuron which increased its ownership interest from 46.06% to 49.99%. Additionally, BCV retains an option to purchase an additional 3.05% of Incuron from CBLI.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Basis of Presentation and Consolidation	'
	Basis of Presentation and Consolidation
	The accompanying consolidated financial statements include the accounts of CBLI and its subsidiaries, BioLab 612, Incuron and Panacela. All significant intercompany balances and transactions have been eliminated in consolidation.
	The unaudited consolidated financial statements included herein have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP, for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission, or the SEC. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013, as filed with the SEC.
	In the opinion of the Company’s management, any adjustments contained in the accompanying unaudited consolidated financial statements are of a normal recurring nature, and are necessary to present fairly the financial position of the Company as of September 30, 2014, along with its results of operations for the three and nine month periods ended September 30, 2014 and 2013 and cash flows for the nine month periods ended September 30, 2014 and 2013. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year.
	As of September 30, 2014, the Company had $4.9 million of cash and cash equivalents available for the general use which management believes will be sufficient to support operations into the first quarter of 2015. To ensure continuing operations beyond the first quarter of 2015, management is evaluating all opportunities to secure additional financing, including investments from non-controlling interests, the issuance of equity and additional revenues from the US or Russian governments. Management believes that sufficient sources of financing will be available to support operations into the future, however there can be no assurances at this time. These matters raise substantial doubt about the Company’s ability to continue as a going concern. These financial statements have been prepared under the assumption that the Company will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2014-09, Revenue from Contracts with Customers, which updates the principles for recognizing revenue. ASU 2014-09 also amends the required disclosures of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. The Company is evaluating the potential impacts of the new standard on its existing revenue recognition policies and procedures.
	In June 2014, the FASB issued ASU 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. ASU 2014-12 requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition, and as such, the performance target should not be reflected in estimating the grant-date fair value of the award. ASU 2014-12 is effective for annual reporting periods beginning after December 15, 2015, with early adoption permitted. The Company is evaluating the potential impacts of the new standard on its existing stock-based compensation plans.
	In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, ASU 2014-15 requires that an entity’s management evaluate whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. ASU 2014-15 is effective for annual periods beginning after December 15, 2016 and for interim periods thereafter. The Company is evaluating the potential impacts of this new standard on its quarterly reporting process.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	Of the $7.9 million and $10.0 million of cash and cash equivalents at September 30, 2014 and December 31, 2013, respectively, only $3.5 million at December 31, 2013 consisted of highly liquid investments with maturities of 90 days or less when purchased. These investments consist of commercial paper, short-term debt securities, time deposits and investments in money market funds with commercial banks and financial institutions. As of September 30, 2014, $3.0 million of the Company’s cash and cash equivalents was restricted to the use of its majority-owned subsidiaries, leaving $4.9 million available for general use.
Significant Customers and Accounts Receivable	'
	Significant Customers and Accounts Receivable
	Grant and contract revenue from the U.S. government accounted for 0% and 1.0% of total revenue for the three and nine months ended September 30, 2014, respectively, and 48.1% and 39.5% of total revenue for the three and nine months ended September 30, 2013, respectively. Grant and contract revenue received by the Company’s subsidiaries from Russian government agencies accounted for 100% and 99.0% of total revenues for the three and nine months ended September 30, 2014, respectively, and 51.9% and 60.5% of total revenues for the three and nine months ended September 30, 2013, respectively. Although the Company anticipates ongoing U.S. and Russian government contract and grant revenue, there is no guarantee that these revenue streams will continue in the future.
	Accounts receivable consist of amounts due under reimbursement contracts with certain government and foreign entities. The Company extends unsecured credit to customers under normal trade agreements, which generally require payment within 30 days.
	Management estimates an allowance for doubtful accounts that is based upon management’s review of delinquent accounts and an assessment of the Company’s historical evidence of collections. There were no allowances for doubtful accounts as of September 30, 2014 and December 31, 2013, as the collection history from the Company’s customers indicated that collection was probable.
Intellectual Property	'
	Intellectual Property
	Costs related to filing and pursuing patent applications are recognized as general and administrative expenses, or G&A expenses, as incurred, since the recoverability of such expenditures is uncertain. Upon marketing approval by the U.S. Food and Drug Administration, or FDA, or a respective foreign governing body, such costs will be capitalized and depreciated over the expected life of the related patent.
Accounting for Stock-Based Compensation	'
	Accounting for Stock-Based Compensation
	The 2006 Equity Incentive Plan, as amended, or the Plan, authorizes CBLI to grant (i) options to purchase common stock, (ii) restricted or unrestricted stock units, and (iii) stock appreciation rights, so long as the exercise or grant price of each are at least equal to the fair market value of the stock on the date of grant. As of September 30, 2014, an aggregate of 10.0 million shares of common stock were authorized for issuance under the Plan, of which a total of approximately 1.9 million shares of common stock remained available for future awards. A single participant cannot be awarded more than 400,000 shares annually. Awards granted under the Plan have a contractual life of no more than 10 years. The terms and conditions of equity awards (such as price, vesting schedule, term and number of shares) under the Plan are specified in an award document, and approved by the Company’s board of directors, compensation committee or its management delegees.
	In June 2013, the Company’s stockholders approved the 2013 Employee Stock Purchase Plan, or ESPP, which provides a means by which eligible employees of the Company and certain designated related corporations may be given an opportunity to purchase shares of Common Stock. As of September 30, 2014, there are 2.3 million shares of Common Stock reserved for purchase under the ESPP. The number of shares reserved for purchase under the ESPP increases on January 1 of each calendar year by the lesser of: (i) 10% of the total number of shares of Common Stock outstanding on December 31st of the preceding year, or (ii) 200,000 shares of Common Stock. The ESPP allows employees to use up to 15% of their compensation to purchase shares of Common Stock at an amount equal to 85% of the fair market value of the Company’s Common Stock on the offering date or the purchase date, whichever is less.
	The Company utilizes the Black-Scholes valuation model for estimating the fair value of all stock options granted where the vesting period is based on length of service or performance, while a Monte Carlo simulation model is used for estimating the fair value of stock options with market-based vesting conditions. Set forth below are the assumptions used in valuing the stock options granted and a discussion of the Company’s methodology for developing each of the assumptions used:
		For the nine months ended September 30,
		2014		2013
	Risk-free interest rate	1.59 - 1.98%		0.02 - 1.92%
	Expected dividend yield	0%		0%
	Expected life	5 - 6 Years		5 - 7.3 Years
	Expected volatility	71.24 - 77.99%		80.71 - 89.66%
	“Risk-free interest rate” means the range of U.S. Treasury rates with a term that most closely resembles the expected life of the option as of the date the option is granted.
	“Expected dividend yield” means the Company does not pay regular dividends on its common stock and does not anticipate paying any dividends in the foreseeable future.
	“Expected life” means the period of time that options granted are expected to remain outstanding, based wholly on the use of the simplified (safe harbor) method. The simplified method is used because the Company does not yet have adequate historical exercise information to estimate the expected life the options granted.
	“Expected volatility” means a measure of the amount by which a financial variable, such as share price, has fluctuated (historical volatility) or is expected to fluctuate (implied volatility) during a period. Expected volatility is based on the Company’s historical volatility and incorporates the volatility of the common stock of comparable companies when the expected life of the option exceeds the Company’s trading history.
Income Taxes	'
	Income Taxes
	No income tax expense was recorded for the three and nine months ended September 30, 2014 and 2013, as the Company does not expect to have taxable income for 2014 and did not have taxable income in 2013. A full valuation allowance has been recorded against the Company’s deferred tax asset.
Earnings (Loss) per Share	'
	Earnings (Loss) per Share
	Basic net income (loss) per share of common stock excludes dilution for potential common stock issuances and is computed by dividing net income (loss) by the weighted average number of shares outstanding for the period. Diluted net income (loss) per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. Diluted net loss per share is identical to basic net loss per share as potentially dilutive securities have been excluded from the calculation of diluted net loss per common share because the inclusion of such securities would be antidilutive.
	The Company has excluded the following outstanding warrants and options from the calculation of diluted net loss per share because all such securities were antidilutive for the periods presented:
		As of September 30,
	Common Equivalent Securities	2014			2013
	Warrants		18,565,024			10,534,245
	Options		5,799,914			5,608,912
	Total		24,364,938			16,143,157
Contingencies	'
	Contingencies
	From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business. The Company accrues for liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. For all periods presented, the Company is not a party to any pending material litigation that is estimable and probable of loss.

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2014
Summary of Assumptions Used in Valuing Stock Options Granted	'
	The Company utilizes the Black-Scholes valuation model for estimating the fair value of all stock options granted where the vesting period is based on length of service or performance, while a Monte Carlo simulation model is used for estimating the fair value of stock options with market-based vesting conditions. Set forth below are the assumptions used in valuing the stock options granted and a discussion of the Company’s methodology for developing each of the assumptions used:
		For the nine months ended September 30,
		2014		2013
	Risk-free interest rate	1.59 - 1.98%		0.02 - 1.92%
	Expected dividend yield	0%		0%
	Expected life	5 - 6 Years		5 - 7.3 Years
	Expected volatility	71.24 - 77.99%		80.71 - 89.66%
Summary of Option Award Activity	'
	The Company has granted options to purchase shares of common stock. The following is a summary of option award activity during the nine months ended September 30, 2014:
		Nine Months Ended September 30, 2014
		Total Stock			Weighted Average		Nonvested Stock			Weighted Average
		Options			Exercise Price per		Options			Grant Date Fair
		Outstanding			Share					Value per Share
	December 31, 2013		5,564,833		$	4.14		594,479		$	1.5
	Granted		991,000			0.62		48,125			0.34
	Vested		—			—		(96,875	)		2.68
	Exercised		—			—		—			—
	Forfeited, Canceled		(755,919	)		4.3		(113,750	)		1.45
	September 30, 2014		5,799,914		$	3.52		431,979		$	1.11
Summary of Outstanding Stock Options	'
	The following is a summary of outstanding stock options as of September 30, 2014:
		As of September 30, 2014
		Stock Options			Vested Stock
		Outstanding			Options
	Quantity		5,799,914			5,367,935
	Weighted-average exercise price	$	3.52		$	3.69
	Weighted Average Remaining Contractual Term (in Years)		6.6			6.43
	Intrinsic value	$	—		$	—
Warrants [Member]	'
Summary of Assumptions Used in Valuing Stock Options Granted	'
	The fair value of the Series A and B warrants amounted to $2,283,092 and was determined based on the following assumptions using the Black-Scholes valuation model:
		September 30, 2014
	Stock Price	$	1.23
	Exercise Price	$	1.22
	Term in years		0.75 - 2.50
	Volatility		43.06 - 79.86	%
	Annual rate of quarterly dividends		0	%
	Discount rate- bond equivalent yield		0.09 - 0.58	%

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	'
	The Company has excluded the following outstanding warrants and options from the calculation of diluted net loss per share because all such securities were antidilutive for the periods presented:
		As of September 30,
	Common Equivalent Securities	2014		2013
	Warrants		18,565,024		10,534,245
	Options		5,799,914		5,608,912
	Total		24,364,938		16,143,157

Fair_Value_of_Financial_Instru1

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Hierarchy for Financial Liabilities Measured on Recurring Basis	'
	The following tables represent the Company’s fair value hierarchy for its financial liabilities measured at fair value on a recurring basis as of September 30, 2014 and December 31, 2013:
			As of September 30, 2014
			Level 1			Level 2			Level 3			Total
	Liabilities:
	Accrued warrant liability		$	—		$	—		$	1,861,013		$	1,861,013
	Total liabilities		$	—		$	—		$	1,861,013		$	1,861,013
			As of December 31, 2013
			Level 1			Level 2			Level 3			Total
	Liabilities:
	Accrued warrant liability		$	—		$	—		$	1,241,311		$	1,241,311
	Compensatory stock options not yet issued			—			—			309,450			309,450
	Total liabilities		$	—		$	—		$	1,550,761		$	1,550,761
Schedule of Share-Based Payment Award Warrant Liability Valuation Assumptions	'
	The Company uses the Black-Scholes model to measure the accrued warrant liability and its accrual for compensatory stock options not yet issued. The following are the assumptions used to measure the accrued warrant liability at September 30, 2014 and December 31, 2013, which were determined in a manner consistent with that described for grants of options to purchase common stock as set forth in Note 2:
			September 30, 2014			December 31, 2013
	Stock Price		$	0.46		$	1.17
	Exercise Price		$	0.505 - 5.00		$	1.60 - 5.00
	Term in years			0.40 - 6.29			0.59 - 1.91
	Volatility			66.57 - 86.88	%		42.52 - 76.03	%
	Annual rate of quarterly dividends			0	%		0	%
	Discount rate- bond equivalent yield			0.05 - 1.78	%		0.08 - 0.36	%
Summary of Changes in Fair Value of Company's Level 3 Fair Value Measurements	'
	The following table sets forth a summary of changes in the fair value of the Company’s Level 3 fair value measurements for the nine months ended September 30, 2014 and 2013:
			Three months ended September 30, 2014						Nine months ended September 30, 2014
			Accrued Warrant			Compensatory			Accrued Warrant			Compensatory
			Liability			Stock Options			Liability			Stock Options
						Not Yet Issued						Not Yet Issued
	Beginning balance		$	1,024,720		$	—		$	1,241,311		$	309,450
	Issuances			—			—			2,283,092			—
	Total (gains) or losses, realized and unrealized, included in earnings (1)(2)			836,293			—			(1,663,390	)		(21,055	)
	Settlements			—			—			—			(288,395	)
	Balance, September 30, 2014		$	1,861,013		$	—		$	1,861,013		$	—
			Three months ended September 30, 2013						Nine months ended September 30, 2013
			Accrued Warrant			Compensatory			Accrued Warrant			Compensatory
			Liability			Stock Options			Liability			Stock Options
						Not Yet Issued						Not Yet Issued
	Beginning balance		$	4,757,770		$	63,838		$	4,105,659		$	—
	Total (gains) or losses, realized and unrealized, included in earnings (1)			(1,163,029	)		—			(510,918	)		—
	Estimates and other changes in fair value (2)			—			102,945			—			166,783
	Balance, September 30, 2013		$	3,594,741		$	166,783		$	3,594,741		$	166,783
	-1	Unrealized gains or losses related to the accrued warrant liability were included as change in value of accrued warrant liability. Realized gains were $95,667 and $0 during the three months ended September 30, 2014 and 2013, respectively.
	-2	Expenses recorded for compensatory stock options not yet issued are included in research and development expense and general and administrative expense.
Summary of Unobservable Inputs into Fair Value Measurement for Accrued Warrant Liability	'
	The following table summarizes the unobservable inputs into the fair value measurement for the accrued warrant liability as of September 30, 2014:
			September 30, 2014
	Description		Fair Value			Valuation Technique		Unobservable Input	Range
	Accrued warrant liability		$	1,861,013		Black-scholes pricing model		Expected term - Years	0.40 - 6.29

Debt_Tables

Debt (Tables)	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Summary of Remaining Principal Payments	'
	The following schedule shows the remaining principal payments due under the Hercules Loan ($2.0 million as of September 30, 2014) for each of the twelve month periods commencing October 1, along with the End-of-Term Fee, and the Rusnano Loan, assuming the loan and compounded interest are paid at maturity in September 2015.
		September 30,
		Hercules		Rusnano		Total
		Loan		Loan
	2015	$	671,184	$	2,125,093	$	2,796,277
	2016		745,662		—		745,662
	2017		1,133,154		—		1,133,154
	2018		—		—		—
	2019		—		—		—
	Thereafter		—		—		—
		$	2,550,000	$	2,125,093	$	4,675,093

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Accounting Policies [Line Items]	'	'	'	'	'	'
Cash and cash equivalents at carrying value	$7,877,432	$14,312,921	$7,877,432	$14,312,921	$10,048,466	$25,652,083
Other cash and cash equivalents at carrying value	'	'	'	'	3,500,000	'
General use cash total	4,900,000	'	4,900,000	'	'	'
Allowances for doubtful accounts	0	'	0	'	0	'
Share-based compensation arrangement by share-based payment award, number of shares authorized	10,000,000	'	10,000,000	'	'	'
Share-based compensation arrangement by share-based payment award, number of shares available for grant	1,900,000	'	1,900,000	'	'	'
Share-based compensation arrangement by share-based payment award number of shares limited per year	'	'	400,000	'	'	'
Share-based compensation arrangement by share-based payment award, equity instruments other than options, outstanding, weighted average remaining contractual terms	'	'	'10 years	'	'	'
Income tax expense	0	0	0	0	'	'
2013 ESPP Plan [Member]	'	'	'	'	'	'
Accounting Policies [Line Items]	'	'	'	'	'	'
Share-based compensation arrangement by share-based payment award, number of shares available for grant	2,300,000	'	2,300,000	'	'	'
Percentage of the total number of shares of common stock outstanding of the preceding year	'	'	10.00%	'	'	'
Share-based compensation arrangement by share-based payment award, number of shares limited per year	200,000	'	200,000	'	'	'
Share-based compensation arrangement by share-based payment award, maximum employee subscription rate	15.00%	'	15.00%	'	'	'
Share-based compensation arrangement by share-based payment award, discount from market price, offering rate	'	'	85.00%	'	'	'
Accounts Receivable [Member]	'	'	'	'	'	'
Accounting Policies [Line Items]	'	'	'	'	'	'
Credit term	'	'	'30 days	'	'	'
Grant and Contract Revenue from U.S. [Member]	'	'	'	'	'	'
Accounting Policies [Line Items]	'	'	'	'	'	'
Concentration risk percentage	0.00%	48.10%	1.00%	39.50%	'	'
Grant and Contract Revenue from Outside Non Domestic [Member]	'	'	'	'	'	'
Accounting Policies [Line Items]	'	'	'	'	'	'
Concentration risk percentage	100.00%	51.90%	99.00%	60.50%	'	'
Panacela [Member]	'	'	'	'	'	'
Accounting Policies [Line Items]	'	'	'	'	'	'
Restricted cash and cash equivalents	$3,000,000	'	$3,000,000	'	'	'

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Summary of Assumptions Used in Valuing Stock Options Granted (Detail)

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2013

Employee Stock Option [Member]

Employee Stock Option [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Employee Stock Option [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Risk-free interest rate

'

'

'

'

0.05%

0.08%

1.59%

0.02%

1.78%

0.36%

1.98%

1.92%

Expected dividend yield

0.00%

0.00%

0.00%

0.00%

'

'

'

'

'

'

'

'

Expected life

'

'

'

'

'4 months 24 days

'7 months 2 days

'5 years

'5 years

'6 years 3 months 15 days

'1 year 10 months 28 days

'6 years

'7 years 3 months 18 days

Expected volatility

'

'

'

'

66.57%

42.52%

71.24%

80.71%

86.88%

76.03%

77.99%

89.66%

Summary_of_Significant_Account5

Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive securities	24,364,938	16,143,157
Warrants [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive securities	18,565,024	10,534,245
Employee Stock Option [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive securities	5,799,914	5,608,912

Fair_Value_of_Financial_Instru2

Fair Value of Financial Instruments - Fair Value Hierarchy for Financial Liabilities Measured on Recurring Basis (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Liabilities:	'	'
Accrued warrant liability	$1,861,013	$1,241,311
Compensatory stock options not yet issued	'	309,450
Total liabilities	1,861,013	1,550,761
Level 1 [Member]	'	'
Liabilities:	'	'
Accrued warrant liability	'	'
Compensatory stock options not yet issued	'	'
Total liabilities	'	'
Level 2 [Member]	'	'
Liabilities:	'	'
Accrued warrant liability	'	'
Compensatory stock options not yet issued	'	'
Total liabilities	'	'
Level 3 [Member]	'	'
Liabilities:	'	'
Accrued warrant liability	1,861,013	1,241,311
Compensatory stock options not yet issued	'	309,450
Total liabilities	$1,861,013	$1,550,761

Fair_Value_of_Financial_Instru3

Fair Value of Financial Instruments - Schedule of Share-Based Payment Award Warrant Liability Valuation Assumptions (Detail) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Jun. 20, 2014	Jan. 16, 2014
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'	'	'
Stock Price	$0.46	$1.17	$0.57	$1.22
Annual rate of quarterly dividends	0.00%	0.00%	'	'
Minimum [Member]	'	'	'	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'	'	'
Exercise Price	$0.51	$1.60	'	'
Term in years	'4 months 24 days	'7 months 2 days	'	'
Volatility	66.57%	42.52%	'	'
Discount rate-bond equivalent yield	0.05%	0.08%	'	'
Maximum [Member]	'	'	'	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'	'	'
Exercise Price	$5	$5	'	'
Term in years	'6 years 3 months 15 days	'1 year 10 months 28 days	'	'
Volatility	86.88%	76.03%	'	'
Discount rate-bond equivalent yield	1.78%	0.36%	'	'

Fair_Value_of_Financial_Instru4

Fair Value of Financial Instruments - Summary of Changes in Fair Value of Company's Level 3 Fair Value Measurements (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Accrued Warrant Liability [Member]	'	'	'	'
Beginning balance	$1,024,720	$4,757,770	$1,241,311	$4,105,659
Issuances	'	'	2,283,092	'
Total (gains) or losses, realized and unrealized, included in earnings	836,293	-1,163,029	-1,663,390	-510,918
Settlements	'	'	'	'
Estimates and other changes in fair value	'	'	'	'
Ending balance	1,861,013	3,594,741	1,861,013	3,594,741
Compensatory Stock Options Not Yet Issued [Member]	'	'	'	'
Beginning balance	'	63,838	309,450	'
Issuances	'	'	'	'
Total (gains) or losses, realized and unrealized, included in earnings	'	'	-21,055	'
Settlements	'	'	-288,395	'
Estimates and other changes in fair value	'	102,945	'	166,783
Ending balance	'	$166,783	'	$166,783

Fair_Value_of_Financial_Instru5

Fair Value of Financial Instruments - Summary of Changes in Fair Value of Company's Level 3 Fair Value Measurements (Parenthetical) (Detail) (USD $)	3 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Debt Instrument Fair Value Carrying Value [Abstract]	'	'
Realized gains or losses	$95,667	$0

Fair_Value_of_Financial_Instru6

Fair Value of Financial Instruments - Additional Information (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Debt Instrument Fair Value Carrying Value [Abstract]	'	'
Assets or liabilities	$0	$0

Fair_Value_of_Financial_Instru7

Fair Value of Financial Instruments - Summary of Unobservable Inputs into Fair Value Measurement for Accrued Warrant Liability (Detail) (Accrued Warrant Liability [Member], USD $)	9 Months Ended
	Sep. 30, 2014
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'
Fair Value	$1,861,013
Valuation Technique	'Black-scholes pricing model
Unobservable Input	'Expected term - Years
Minimum [Member]	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'
Range	'4 months 24 days
Maximum [Member]	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'
Range	'6 years 3 months 15 days

Debt_Additional_Information_De

Debt - Additional Information (Detail) (USD $)	0 Months Ended		9 Months Ended	0 Months Ended	6 Months Ended	9 Months Ended		9 Months Ended
	Jun. 20, 2014	Jan. 16, 2014	Sep. 30, 2014	Sep. 30, 2014	Jun. 30, 2014	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 03, 2013
				Hercules Technology II, L.P. [Member]	Hercules Technology II, L.P. [Member]	Hercules Technology II, L.P. [Member]	Hercules Technology II, L.P. [Member]	Rusnano Loan [Member]	Rusnano Loan [Member]
Debt Instrument [Line Items]	'	'	'	'	'	'	'	'	'
Debt Instrument, Face Amount	'	'	'	'	'	'	$6,000,000	'	$1,530,000
Debt instrument, fee amount	'	'	'	'	'	'	550,000	'	0
Debt instrument, fee description	'	'	'	'In addition to interest and principle payments, the Hercules Loan requires payment of $550,000 at maturity, or upon full repayment if sooner, bEnd-of-Term Feeb.	'	'	'	'	'
Repayment of long term debt	'	'	'	'	4,000,000	'	'	'	'
Net proceeds from sale of equity	3,300,000	6,400,000	9,697,501	'	3,300,000	'	'	'	'
Remaining principal payments	'	'	'	'	'	2,000,000	'	'	'
Debt Instrument Penalty rate	'	'	'	'	3.00%	'	'	'	'
Repayments of debt	'	'	'	'	$700,000	'	'	'	'
Debt instrument, maturity date	'	'	'	'	'	'	'	30-Sep-15	'

Debt_Summary_of_Remaining_Prin

Debt - Summary of Remaining Principal Payments (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Debt Instrument [Line Items]	'	'
Total	$3,479,396	$7,121,388
Hercules Technology II, L.P. [Member]	'	'
Debt Instrument [Line Items]	'	'
2015	671,184	'
2016	745,662	'
2017	1,133,154	'
2018	'	'
2019	'	'
Thereafter	'	'
Total	2,550,000	'
Rusnano Loan [Member]	'	'
Debt Instrument [Line Items]	'	'
2015	2,125,093	'
2016	'	'
2017	'	'
2018	'	'
2019	'	'
Thereafter	'	'
Total	2,125,093	'
Hercules Technology II, L.P. and Rusnano [Member]	'	'
Debt Instrument [Line Items]	'	'
2015	2,796,277	'
2016	745,662	'
2017	1,133,154	'
2018	'	'
2019	'	'
Thereafter	'	'
Total	$4,675,093	'

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)

0 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

0 Months Ended

Jun. 20, 2014

Jan. 16, 2014

Sep. 30, 2014

Sep. 30, 2013

Jun. 20, 2014

Jan. 16, 2014

Dec. 31, 2013

Sep. 04, 2014

Sep. 30, 2014

Sep. 04, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 29, 2014

Sep. 04, 2014

Sep. 30, 2014

Sep. 04, 2014

Sep. 30, 2014

Sep. 29, 2014

Jun. 20, 2014

Jan. 16, 2014

Jan. 16, 2014

Jun. 20, 2014

Jan. 16, 2014

Jan. 16, 2014

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Accrued Warrant Liability [Member]

Accrued Warrant Liability [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series D Warrants [Member]

Purchasers [Member]

Purchasers [Member]

Purchasers [Member]

Placement Agent [Member]

Placement Agent [Member]

Placement Agent [Member]

Accrued Warrant Liability [Member]

Accrued Warrant Liability [Member]

Series J [Member]

Series A Warrants [Member]

Series B Warrants [Member]

Series J [Member]

Series A Warrants [Member]

Series B Warrants [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares issued in public offering

6,167,400

5,737,706

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of warrants issued

3,083,700

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,083,700

2,868,853

2,868,853

26,432

86,066

86,066

Common stock at a price

'

'

$0.46

'

$0.57

$1.22

$1.17

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Issuance of Common Stock

$3,300,000

$6,400,000

$9,697,501

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants exercisable price per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.56

$1.22

$1.22

$0.56

'

'

Warrants expiration period from the date of issuance

'

'

'

'

'

'

'

'

'1 year

'

'7 years

'

'

'

'

'

'

'

'

'5 years

'5 years

'18 months

'5 years

'

'

Number of warrants adjusted due to reduction in exercise price

'

'

'

'

4,577,444

4,421,195

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price of warrants

'

'

$1.69

'

$0.51

$1.22

'

'

$0.51

'

$5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants exercisable period from the date of issuance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'9 months

'9 months

'

'

'

Fair value of warrants

'

'

'

'

'

'

'

'

'

'

'

'

2,283,092

'

'

2,283,092

'

2,283,092

'

'

'

'

'

'

'

Common stock shares , repurchase

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,049,180

'

2,049,180

'

3,485,810

'

'

'

'

'

'

Warrant or Right, Date from which Warrants or Rights Exercisable

'

'

'

'

'

'

'

'

'

'

'

'

'

16-Jan-21

'

'

'

'

30-Mar-18

'

'

'

'

'

'

Common stock exercise price, maximum

'

'

'

'

'

'

'

$1.02

'

$1.22

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures

'

'

991,000

898,604

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based compensation arrangement by share-based payment award, options, grants in period, weighted-average grant date fair value

'

'

$0.38

$1.21

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based compensation arrangement by share-based payment award, options, vested in period, fair value

'

'

261,283

858,037

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Employee Service Share-based Compensation, non-vested awards, total compensation cost not yet recognized

'

'

$128,913

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Employee Service Share-based Compensation, non-vested awards, total compensation cost not yet recognized, period for recognition

'

'

'5 months 27 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders_Equity_Warrants_D

Stockholders' Equity - Warrants Determined by Black-Scholes Valuation Model with Following Assumptions (Detail) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Jun. 20, 2014	Jan. 16, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock Price	$0.46	$1.17	$0.57	$1.22
Annual rate of quarterly dividends	0.00%	0.00%	'	'
Minimum [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Exercise Price	$0.51	$1.60	'	'
Term in years	'4 months 24 days	'7 months 2 days	'	'
Volatility	66.57%	42.52%	'	'
Discount rate- bond equivalent yield	0.05%	0.08%	'	'
Maximum [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Exercise Price	$5	$5	'	'
Term in years	'6 years 3 months 15 days	'1 year 10 months 28 days	'	'
Volatility	86.88%	76.03%	'	'
Discount rate- bond equivalent yield	1.78%	0.36%	'	'
Black Scholes Stock Price Valuation Model [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock Price	$1.23	'	'	'
Exercise Price	$1.22	'	'	'
Annual rate of quarterly dividends	0.00%	'	'	'
Black Scholes Stock Price Valuation Model [Member] | Minimum [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Term in years	'9 months	'	'	'
Volatility	43.06%	'	'	'
Discount rate- bond equivalent yield	0.09%	'	'	'
Black Scholes Stock Price Valuation Model [Member] | Maximum [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Term in years	'2 years 6 months	'	'	'
Volatility	79.86%	'	'	'
Discount rate- bond equivalent yield	0.58%	'	'	'

Stockholders_Equity_Summary_of

Stockholders' Equity - Summary of Option Award Activity (Detail) (USD $)	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
Total Stock Options Outstanding, Beginning balance	5,564,833
Total Stock Options Outstanding, Granted	991,000
Total Stock Options Outstanding, Vested	'
Total Stock Options Outstanding, Exercised	'
Total Stock Options Outstanding, Forfeited, Canceled	-755,919
Total Stock Options Outstanding, Ending balance	5,799,914
Weighted Average Exercise Price per Share, Beginning balance	$4.14
Weighted Average Exercise Price per Share, Granted	$0.62
Weighted Average Exercise Price per Share, Vested	'
Weighted Average Exercise Price per Share, Exercised	'
Weighted Average Exercise Price per Share, Forfeited, Canceled	$4.30
Weighted Average Exercise Price per Share, Ending balance	$3.52
Nonvested Stock Options, Beginning balance	594,479
Nonvested Stock Options, Granted	48,125
Nonvested Stock Options, Vested	-96,875
Nonvested Stock Options, Exercised	'
Nonvested Stock Options, Forfeited, Canceled	-113,750
Nonvested Stock Options, Ending balance	431,979
Weighted Average Grant Date Fair Value per Share, Beginning balance	$1.50
Weighted Average Grant Date Fair Value per Share, Granted	$0.34
Weighted Average Grant Date Fair Value per Share, Vested	$2.68
Weighted Average Grant Date Fair Value per Share, Exercised	'
Weighted Average Grant Date Fair Value per Share, Forfeited, Canceled	$1.45
Weighted Average Grant Date Fair Value per Share, Ending balance	$1.11

Stockholders_Equity_Summary_of1

Stockholders' Equity - Summary of Outstanding Stock Options (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014
			Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Stock Options Outstanding, Quantity	5,799,914	5,564,833	5,799,914
Stock Options Outstanding, Weighted-average exercise price	$3.52	$4.14	$3.52
Stock Options Outstanding, Weighted Average Remaining Contractual Term (in Years)	'	'	'6 years 7 months 6 days
Stock Options Outstanding, Intrinsic value	'	'	'
Vested Stock Options, Quantity	'	'	5,799,914
Vested Stock Options, Weighted-average exercise price	'	'	$3.52
Vested Stock Options, Weighted Average Remaining Contractual Term (in Years)	'	'	'6 years 5 months 5 days
Vested Stock Options, Intrinsic value	'	'	'

Warrants_Additional_Informatio

Warrants - Additional Information (Detail) (USD $)	9 Months Ended
	Sep. 30, 2014	Jun. 20, 2014	Jan. 16, 2014
Class of Warrant or Right [Line Items]	'	'	'
Class of warrants or right, number of securities called by warrants or rights (in shares)	17,505,032	'	'
Class of warrants or right, exercise price of warrants or rights	$1.69	$0.51	$1.22
Warrants termination date	31-Dec-16	'	'
Rusnano Warrant [Member]	'	'	'
Class of Warrant or Right [Line Items]	'	'	'
Class of warrants or right, number of securities called by warrants or rights (in shares)	739,920	'	'
Rusnano default commitment	'In addition, the Company has issued a warrant to Rusnano, our financial partner in Panacela, that can only be exercised in the event Panacela defaults on a loan from Rusnano, the "Rusnano Warrant" and the "Rusnano Loan."	'	'
Minimum [Member]	'	'	'
Class of Warrant or Right [Line Items]	'	'	'
Class of warrants or right, exercise price of warrants or rights	$0.51	'	'
Warrants expiration term	'1 year	'	'
Maximum [Member]	'	'	'
Class of Warrant or Right [Line Items]	'	'	'
Class of warrants or right, exercise price of warrants or rights	$5	'	'
Warrants expiration term	'7 years	'	'
Maximum [Member] | Rusnano Warrant [Member]	'	'	'
Class of Warrant or Right [Line Items]	'	'	'
Class of warrants or right, number of securities called by warrants or rights (in shares)	1,059,992	'	'

Noncontrolling_Interests_Addit

Noncontrolling Interests - Additional Information (Detail)	0 Months Ended					9 Months Ended			9 Months Ended
In Millions, unless otherwise specified	Aug. 05, 2014	Aug. 05, 2014	Jun. 20, 2014	Jun. 20, 2014	Aug. 05, 2014	Sep. 30, 2014	Sep. 30, 2014	Aug. 05, 2014	Sep. 30, 2014	Sep. 30, 2014	Aug. 05, 2014
	Bioprocess Capital Ventures [Member]	Bioprocess Capital Ventures [Member]	Bioprocess Capital Ventures [Member]	Bioprocess Capital Ventures [Member]	Bioprocess Capital Ventures [Member]	Minimum [Member]	Minimum [Member]	Minimum [Member]	Maximum [Member]	Maximum [Member]	Maximum [Member]
	Incuron, LLC [Member]	Incuron, LLC [Member]	Incuron, LLC [Member]	Incuron, LLC [Member]	C B L I [Member]	C B L I [Member]	Bioprocess Capital Ventures [Member]	Bioprocess Capital Ventures [Member]	C B L I [Member]	Bioprocess Capital Ventures [Member]	Bioprocess Capital Ventures [Member]
	USD ($)	RUB	USD ($)	RUB
Noncontrolling Interest [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Payments to acquire additional interest in subsidiaries	$2.30	80	$2.90	100	'	'	'	'	'	'	'
Noncontrolling interest, ownership percentage by noncontrolling owners	'	'	'	'	3.05%	'	40.78%	46.06%	'	46.06%	49.99%
Ownership interest in Incuron, LLC majority-owned subsidiary	'	'	'	'	'	59.22%	'	'	53.94%	'	'